Nov. 17, 2009 (PR Newswire) — CORALVILLE, Iowa, Nov. 17 /PRNewswire-FirstCall/ — Vivakor, Inc. (OTC Bulletin Board: VIVK) today announced that its Board of Directors approved a dividend of shares of common stock of HealthAmerica, Inc., a Nevada corporation of which Vivakor owns approximately 84% of the outstanding common stock. Each Vivakor shareholder will be entitled to receive one share of HealthAmerica common stock for each share of Vivakor common stock beneficially owned on the record date. The record date for the distribution is expected to be December 1, 2009, subject to review and approval of FINRA, and the distribution date is expected to be December 9, 2009. After the dividend distribution, Vivakor will continue to own approximately 62% of the outstanding common stock of HealthAmerica.

Vivakor shareholders will not be required to take any action to receive the HealthAmerica common shares on the distribution date.

Vivakor Chairman Matt Nicosia

Nov. 11, 2009 (Business Wire) — Vivakor, Inc. (OTCBB: VIVK) today announced it has completed an exclusive distribution agreement with consumer product specialist, Regeneca International, Inc. (www.regeneca.com) for one of its proprietary, cutting-edge nutraceutical formulations. In conjunction with this agreement was an immediate purchase order from Regeneca for 25,000 units of the product. Both companies hope this agreement initiates a long term relationship for product commercialization. This purchase also represents to another substantial revenue stream for Vivakor’s emerging nutraceutical division. Vivakor CEO Tannin Fuja expressed his enthusiasm for the transaction. “We are very excited for the possibilities of Vivakor’s line of nutraceutical products. Worldwide demand for nutraceutical products is expected to exceed $15 billion and Vivakor plans on being a substantial player in that market.”

Dr. Fuja continued, “We are particularly pleased to include in our new formulation the powerful, super-antioxidant star Yumberry (yang-mei in Chinese) also

Nov. 9, 2009 (Business Wire) — Vivakor, Inc. (OTCBB: VIVK) today announced it has completed a pilot product evaluation program with consumer product specialist, Regeneca International, Inc. (www.regeneca.com). The product evaluation involved Vivakor’s proprietary nutraceutical formulation derived from natural sources. Research has shown that phytochemicals, vitamins, minerals, and fiber, all present in fruits and vegetables, work synergistically to promote health and lower disease risk. For this reason, many organizations, such as the National Cancer Institute and The American Heart Association, recommend getting phytochemicals from whole foods, such as fruits and vegetables. The Vivakor product is a whole food supplement designed to deliver these essential nutrients to the users in small, single dose units.

Regeneca’s President, Larry Walter gave his thoughts on the study. “Not only are the consumer study results impressive, but the overall opportunity to work with the team of professionals at Vivakor gives us a great deal

Oct. 8, 2009 (Business Wire) — Vivakor, Inc. (OTCBB: VIVK) announces distribution of its VivaThermic products to the rapidly growing biotech/biopharma industries in India through its agreement with Pro Lab Marketing Pvt. Ltd. This agreement gives Pro Lab Marketing distribution rights for Vivakor’s VivaThermic cryovials in India. Pro Lab Marketing, based in New Delhi, is a well-established Indian supplier of biotechnology-related products and equipment throughout India. “We are impressed with the VivaThermic products and their outstanding performance,” stated Mr. J.K. Jain, Managing Director of Pro Lab Marketing. He continues, “Through our distribution agreement with Vivakor we will introduce the VivaThermic products to our customers throughout India who will benefit greatly from use of this technology.”

Vivakor’s CEO, Dr. Tannin Fuja, indicated that, “The Indian biotechnology industry is gaining significant momentum and India figures to become a prominent player in the global biotech market. A number of India’s biotech firms